19
November

08:00 AM EST

Bioinformatics

Name: Drug Discovery Biology Strategy Meeting East Coast 2025 (Boston)
Start: 2025-11-19T08:00
End: 2025-11-19T18:00
Location: Crowne Plaza, London Docklands

&

Drug Discovery Biology

Strategy Meeting East Coast USA 2025

Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space

Le Méridien Boston Cambridge

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Biology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.

Aditya Ambade, Ph.D

Director Business Development Discovery Biology SAI Life Sciences

Ajita V. Singh, Ph.D

Associate Director, Discovery Biology SAI Life Sciences

Atli Thorarensen

Vice President, Head of Chemistry Cellarity

Bill Jackson, Ph.D

Founder & CEO Base Pair Biotechnologies, Inc.

Charles Sinclair

Vice President, Translation Sciences Pioneering Medicines

Christina Ansted

Senior Managing Partner RCP Venture Capital

Dan Rozelle

Vice President, Data Analytics Rancho Biosciences

David Sherris

CEO Attivare Therapeutics

Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors 
Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Eric Ma

Senior Principal Data Scientist Moderna

Fatemeh Mojtabai

Founder and CEO Novatarg Theranostics

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Huseyin Mehmet

Executive Director, New Ventures University of Massachusetts Medical School

Huseyin Mehmet is a drug hunter and research scientist with >35 years’ experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UJ and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.

Julia Fox

Director Takeda

Lakshmi Muthuswamy

Senior Director and Head, Computational Biology and Data Science Blueprint Medicines

Larry Mulcahy, Ph.D.

Product Manager, Biologics Revvity Signals

Lijuan Jiang

Vice President, DMPK & Bioanalysis Enanta Pharmaceuticals

Michael Janes

Co Founder – Chief Revenue Officer RCP Venture Capital

Mohamed Kassam

Head, Bioinformatics Zifo

Nathan McBride

Chief Information Officer Xilio Therapeutics, Inc.

Prasoon Chaturvedi

Vice President, Head of DMPK C4 Therapeutics, Inc.

Prateek Katti

Investor Newpath Partners

Richard Heidebrecht

Vice President of Research and Development Glycologix

Shengwen Zhang

Executive Director QLD Biotherapeutics

Zev Wisotsky

Director, Drug Discovery New Modality Solutions Revvity Signals

Winnie Tam

Scientific Director, Head of Precision Medicine Immunology Translation Research AbbVie

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

Target Identification & Hit Validation
Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification

-Richard Heidebrecht
Vice President of Research and Development
Glycologix

DMPK / ADME Toxicology
Bridging Preclinical Models and Human Safety: Innovations in DMPK and Toxicology (Topic TBC)

-Mohammad Shadid
Vice President, Preclinical and Translational Sciences
Korro Bio

In Vivo and In Vitro Pharmacology
Improving Translational Predictability: Enhancing PK/PD Models, Biomarkers, and Multi- Scale Integration in Preclinical Pharmacology

Data Management, Big Data & Digital Transformation
Accelerating Bioinformatics Pipelines with Next-Generation Data Platforms: Lessons from High-Performance Infrastructure at Scale

Data Integration / AI & ML
Innovating In Silico Drug Design through AI and ML

-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Bioinformatics & Digital Transformation
AI-Powered Bioinformatics: The Engine of Digital Transformation in Biology

-Winnie Tam
Scientific Director, Head of Precision Medicine Immunology Translation Research
AbbVie

Private Equity, Venture Capital & Strategic ESTPartnerships
Early-Stage Science, Late-Stage Discipline: What Today’s Investors Want

-Christina Ansted
Senior Managing Partner
RCP Venture Capital

-Michael Janes
Co Founder – Chief Revenue Officer
RCP Venture Capital

11:10 – 12:10

Roundtable Tracks

Target Identification & Hit Validation
Target Identification and Hit Validation: Bridging Biology and Chemistry

-Ajita V. Singh, Ph.D
Associate Director, Discovery Biology
SAI Life Sciences

SAI LIFE SCIENCES

DMPK / ADME Toxicology
Alternative (non-antibody-based) affinity reagents in therapeutic development

-Bill Jackson, Ph.D
Founder & CEO
Base Pair Biotechnologies, Inc.

Sponsor

In Vivo and In Vitro Pharmacology
Translating Biology: Advances in In Vitro and In Vivo Pharmacology

-Aditya Ambade, Ph.D
Director Business Development Discovery Biology
SAI Life Sciences

SAI LIFE SCIENCES

Data Management, Big Data & Digital Transformation
The Data Integration Crisis in Drug Discovery

-Zev Wisotsky
Director, Drug Discovery New Modality Solutions
Revvity Signals

REVVITY SIGNALS

Data Integration / AI & ML
Beyond the ELN: Turning Data Chaos into Connected Discover

-Larry Mulcahy, Ph.D.
Product Manager, Biologics
Revvity Signals

REVVITY SIGNALS

Bioinformatics & Digital Transformation
Accelerate Insights by Democratizing AI-Ready Data for your Organization

-Dan Rozelle
Vice President, Data Analytics
Rancho Biosciences

RANCHO BIOSCIENCES

Private Equity, Venture Capital & Strategic ESTPartnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery

Sponsor

12:15 – 13:15

Roundtable Tracks

Target Identification & Hit Validation
Unveiling Membrane Protein Dynamics in Native States: Next Generation Structural Tools for Drug Discovery

-Fatemeh Mojtabai
Founder and CEO
Novatarg Theranostics

DMPK / ADME Toxicology
Developments in Predictive Modeling and Metabolic Profiling for Advancing Drug Discovery with DMPK (Topic TBC)

-Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

In Vivo and In Vitro Pharmacology
Translating Preclinical Experiments to Clinic Application

-Shengwen Zhang
Executive Director
QLD Biotherapeutics

Data Management, Big Data & Digital Transformation
Hard-Won Lessons, and Questions, Making Laboratory Data Machine Learning Ready

-Eric Ma
Senior Principal Data Scientist
Moderna

Data Integration / AI & ML
AI-Powered Drug Discovery Trends and Challenges in 2025

-Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

Bioinformatics & Digital Transformation
Towards Transparent and Inclusive Innovation: Balancing the Power of Data Mining and Data Science with the Need for Human-Centric AI

-Julia Fox
Director
Takeda

Private Equity, Venture Capital & Strategic ESTPartnerships
Early-Stage Science, Late-Stage Discipline: What Today’s Investors Want

-Prateek Katti
Investor
Newpath Partners

15:10 – 16:10

Roundtable Tracks

Target Identification & Hit Validation
Turning Novel Biology into Clinical Reality: Integrating Translational Research to Enhance the Success of Emerging Therapeutics

-Charles Sinclair
Vice President, Translation Sciences
Pioneering Medicines

DMPK / ADME Toxicology
Strategies to Optimize ADME Properties in Drug Discovery to Enhance Drug Bioavailability

-Lijuan Jiang
Vice President, DMPK & Bioanalysis
Enanta Pharmaceuticals

In Vivo and In Vitro Pharmacology
Advanced In Vitro Models Enhancing Predictive Accuracy in Drug Discovery

Data Management, Big Data & Digital Transformation
Bridging the Data Divide in Bioinformatics: Innovative Approaches to Data Management and Analysis

Data Integration / AI & ML
Building Robust AI Models for Improved Data Quality and Represent ation in Drug Discovery (Topic TBC)

-Atli Thorarensen
Vice President, Head of Chemistry
Cellarity

Bioinformatics & Digital Transformation
Beyond Buzzwords: What Digital Transformation Really Means in 2025

-Nathan McBride
Chief Information Officer
Xilio Therapeutics, Inc.

Private Equity, Venture Capital & Strategic ESTPartnerships
Private Equity, Venture Capital & Strategic Partnerships

-Huseyin Mehmet
Executive Director, New Ventures
University of Massachusetts Medical School

17:00 – 18:00

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

&

Strategy Meeting East Coast USA 2025

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Méridien Boston Cambridge

Fresh Biology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Aditya Ambade, Ph.D

Ajita V. Singh, Ph.D

Atli Thorarensen

Bill Jackson, Ph.D

Charles Sinclair

Christina Ansted

Dan Rozelle

David Sherris

Diane Joseph-McCarthy

Eric Ma

Fatemeh Mojtabai

Govinda Bhisetti

Huseyin Mehmet

Julia Fox

Lakshmi Muthuswamy

Larry Mulcahy, Ph.D.

Lijuan Jiang

Michael Janes

Mohamed Kassam

Nathan McBride

Prasoon Chaturvedi

Prateek Katti

Richard Heidebrecht

Shengwen Zhang

Zev Wisotsky

Winnie Tam

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable (Solution)

Roundtable Tracks

SAI LIFE SCIENCES

Sponsor

SAI LIFE SCIENCES

REVVITY SIGNALS

REVVITY SIGNALS

RANCHO BIOSCIENCES

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Networking Lunch

Networking/1-1 Meetings

Afternoon Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Sponsors

Thought Leaders

Le Méridien Boston Cambridge